

DELIVERING THE POWER OF T CELLS TO CANCER PATIENTS

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

THE IMMATICS APPROACH

Unlocking new T cell receptor-based immunotherapies by identifying true targets

Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to achieve the next advance in immunotherapy.



We have inner insight

Immatics has identified and characterized a trove of novel intracellular tumor targets for the development of cancer immunotherapies. We use this knowledge together with our XPRESIDENT® technology to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we aim to leverage for our own proprietary pipeline and for our collaborations with world-leading partners.



We pioneer novel therapeutic approaches

TCRs represent a new therapeutic opportunity for engaging T cells against cancer and for attacking the tumor microenvironment. These new treatments are designed to cross cancer's protective barriers and make a therapeutic impact. Immatics continues to innovate using the right TCRs to develop both Adoptive Cell Therapies and novel antibody-like TCR Bispecifics.



We refine and engineer our drug candidates

Through our XCEPTOR™-based process of testing the specificity, affinity and functionality of our TCRs to engage with cancer cells, our drug candidates use the full power of T cells to fight tumor cells.



Our purpose is to make a difference for patients

We have a big goal: overcoming the challenges of fighting cancer and bringing new therapeutic opportunities to cancer patients with high medical need. We will do this with passion and relentless focus to achieve better outcomes for patients.

QUICK FACTS

Established:
2000

Locations:
Tuebingen and Munich, Germany
Houston, Texas, USA

Employees:
200 +

Proprietary pipeline:
7 product candidates, thereof 3 in clinical trials

Partnered pipeline:
10 programs partnered with Amgen, Genmab, BMS, GSK

Cancer targets:
More than 200 prioritized cancer targets across multiple cancer indications

IP position:
Over 1,550 secured patents worldwide and over 320 granted patents in the US

NASDAQ Ticker:
IMTX

Shares Outstanding
62,9 million

SENIOR LEADERSHIP

Harpreet Singh, Ph.D.
Chief Executive Officer

Arnd Christ
Chief Financial Officer

Carsten Reinhardt, M.D., Ph.D.
Chief Development Officer

Cedrik Britten, M.D.
Chief Medical Officer

Rainer Kramer, Ph.D.
Chief Business Officer

Steffen Walter, Ph.D.
Chief Technology Officer

Toni Weinschenk, Ph.D.
Chief Innovation Officer

BOARD of DIRECTORS

Peter Chambré (Chairman)

Adam Stone

Christof Hettich, L.L.D.

Eliot Forster, Ph.D.

Heather Maison

Michael Atieh

Paul Carter, FCMA

Contacts:

Jordan Silverstein
Head of Corporate Strategy
E-Mail: InvestorRelations@immatics.com
Phone: +1 281-810-7545

Anja Heuer
Corporate Communications
E-Mail: media@immatics.com
Phone: +49 89 540415-606



@immatics



<https://www.linkedin.com/company/immatics>



immatics®

www.immatics.com

POTENTIAL OF TCR-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF SOLID CANCERS

FACTS & FIGURES

1 IN 6

deaths are related to cancer, making it the second leading cause of death worldwide.

~90%

of all cancers globally are solid cancers where current immunotherapies have shown only limited success.

~300%

more cancer targets are accessible by TCR-based immunotherapies compared to classical antibodies and CAR-T. These immunotherapies are limited to targets on the cell surface which represent only ~25% of all potential tumor targets.

15%

is the forecasted compound annual growth rate (CAGR) for the solid tumor therapeutics market from 2019 – 2024.


PRODUCT PIPELINE

Immatic's fully-owned pipeline consists of Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER™) directed against various targets relevant in a broad range of cancers. Our proprietary XPRESIDENT® and XCEPTOR™ target and TCR technology platforms build the foundation for our broad pipeline with the goal to overcome the current limitations in immuno-oncology and to improve the outcome for patients with solid cancers.

Product Class	Product Candidate	Indications	Preclinical	Phase 1	Phase 2	Phase 3
Autologous TCR-T ACTEngine®	IMA201 (MAGEA4/8)	Solid cancers	██████████	██████████		
	IMA202 (MAGEA1)	Solid cancers	██████████	██████████		
	IMA203 (PRAME)	Hematological & solid cancers	██████████	██████████		
	IMA204 (COL6A3)	Solid cancers	██████████			
Allogenic v6 T cells ACTallo®	IMA301 (Cancer testis antigen)	Hematological & solid cancers	██████████			
	ACTolog®	IMA101 (Multi-target pilot trial)	██████████	██████████		
TCR Bispecifics TCER™	IMA401 (MAGEA4/8)	Solid cancers		██████████		
	IMA402 (Cancer testis antigen)	Hematological & solid cancers		██████████		

STRATEGIC COLLABORATIONS WITH GLOBAL LEADERS

In addition to our proprietary pipeline, we are developing 10 programs in alliances with global leaders validating our unique technologies and expertise.




Each of the 10 partnered programs may be eligible for

- >\$500 million aggregated milestone payments per program
- Tiered royalties per program

TWO TREATMENT MODALITIES

We are developing targeted TCR-based immunotherapies with an emphasis on hard-to-treat solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACTEngine®) and antibody-like TCR Bispecifics (TCER™). Due to their different mode of action, these modalities are designed to expand the potential therapeutic value for patients across a broad range of tumor types and stages.



Adoptive Cell Therapy (ACT)

Our clinical lead product class ACTEngine® is a personalized approach for patients with advanced solid cancers. The patient's own T cells are genetically modified to express a novel proprietary TCR against the cancer target and is then infused back into the patient. ACTEngine® programs IMA201, IMA202 and IMA203 are already in clinical studies for a broad range of solid tumor indications, both in the US and in Germany. Our fourth ACTEngine® IMA204 program is in pre-clinical stage. It targets the tumor stroma and is designed to disrupt the protective tumor microenvironment. We are further advancing the ACT concept beyond individualized manufacturing with our product class ACTallo® which is being developed to generate "off-the-shelf" cell therapies.

TCR Bispecifics (TCER™)

Our TCER™ molecules are antibody-like "off-the-shelf" biologics engineered to have two binding regions: a TCR which directly recognizes target-positive cancer cells and a T cell recruiter domain which recruits and activates T cells. TCER™ are designed to attract any patient's circulating T cells to bind and come into direct proximity with the cancer to destroy it. Due to their off-the-shelf availability and simple treatment regimen TCER™ have the potential to be cost-effective biologic drug candidates that can be easily distributed.